What Is Malignant Fibrous Histiocytoma?
Malignant fibrous histiocytoma (MFH), now more commonly referred to as undifferentiated pleomorphic sarcoma (UPS) in many classifications, is a type of soft tissue sarcoma that can occur in various parts of the body, including the liver. Although primary MFH of the liver is extremely rare, it represents a highly aggressive tumour arising from the mesenchymal tissue, which can rapidly grow and metastasize if not treated promptly.
Symptoms
Symptoms of MFH in the liver may not be specific and can resemble those of other liver conditions, including:
- Abdominal pain or discomfort, particularly in the upper right quadrant
- A palpable mass in the abdomen
- Unintentional weight loss
- Loss of appetite
- Fatigue and weakness
- Jaundice (yellowing of the skin and eyes), although less common
Disease Aetiology (Causes)
The exact cause of malignant fibrous histiocytoma of the liver is unknown. Like other sarcomas, it may be related to genetic mutations, but specific risk factors for liver involvement have not been clearly identified.
Diagnosis
Diagnosing MFH of the liver typically involves:
- Imaging studies such as ultrasound, computed tomography (CT) scans, and magnetic resonance imaging (MRI) to identify and assess the tumour.
- Blood tests to evaluate liver function and overall health status.
- Biopsy of the liver tissue to obtain a definitive diagnosis, where the tumour cells are examined under a microscope and may undergo further genetic and molecular testing.
Treatment
Treatment options for MFH of the liver are limited and depend on the tumour’s size, location, and whether it has spread:
- Surgery is the primary treatment approach, aiming to remove the tumour and a margin of healthy tissue around it. Due to the liver’s regenerative capacity, resection can be a viable option for localized tumours.
- Chemotherapy may be used before surgery to shrink the tumour or after surgery to target any remaining cancer cells, although its effectiveness can vary.
- Radiation therapy is generally less commonly used for liver tumours but may be considered in specific cases to control tumour growth or alleviate symptoms.
- Targeted therapy and immunotherapy are areas of ongoing research and may offer new options for treatment in the future.
What support can we give for the Malignant Fibrous Histiocytoma (MFH) of the Liver?
Malignant Fibrous Histiocytoma (MFH) of the Liver is a rare cancer, meaning it is not as well-known as other forms of cancer. Without a Ribbon is an Australian organisation that provides support for individuals who suffer from rare cancers. So, we provide a designated platform for Warriors to obtain information specific to their Rare Cancer. We also provide annual opportunities for our Warriors to meet and learn from each other. If you suffer from rare cancer such as Malignant Fibrous Histiocytoma (MFH) of the Liver, we can help and support you through your journey thanks to the generous donations we receive. Click the link below to sign up and become a Warrior today!
You can help us with your donation:
Without a Ribbon is a charity that works hard to aid those who suffer from rare cancers. You can help our cause in a variety of ways:
